Kallum Titchmarsh
Stock Analyst at Morgan Stanley
(4.52)
# 1,228
Out of 5,081 analysts
230
Total ratings
65.7%
Success rate
15.2%
Average return
Main Sectors:
Stocks Rated by Kallum Titchmarsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Reiterated: Buy | $200 | $173.25 | +15.44% | 9 | Oct 20, 2026 | |
| A Agilent Technologies | Rated: Buy | $175 → $190 | $175.96 | +7.98% | 9 | Oct 13, 2026 | |
| ADPT Adaptive Biotechnologies | Reiterated: Hold | $27 | $26.27 | +2.78% | 7 | Oct 13, 2026 | |
| AVTR Avantor | Rated: Hold | $14 → $15 | $17.29 | -13.24% | 3 | Oct 13, 2026 | |
| CRL Charles River Laboratories International | Rated: Buy | $300 → $340 | $357.27 | -4.83% | 10 | Oct 13, 2026 | |
| DHR Danaher | Rated: Buy | $220 → $240 | $232.97 | +3.02% | 10 | Oct 13, 2026 | |
| GRAL GRAIL | Reiterated: Hold | $120 | $139.91 | -14.23% | 9 | Oct 13, 2026 | |
| NTRA Natera | Rated: Buy | $355 → $435 | $404.90 | +7.43% | 8 | Oct 13, 2026 | |
| TMO Thermo Fisher Scientific | Rated: Buy | $650 → $730 | $684.89 | +6.59% | 6 | Oct 13, 2026 | |
| TXG 10x Genomics | Rated: Hold | $40 → $70 | $72.96 | -4.06% | 8 | Oct 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5.5 → $5 | $5.89 | -15.11% | 4 | Oct 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1,450 → $1,575 | $1,669.62 | -5.67% | 6 | Oct 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $20 | $19.88 | +0.60% | 16 | Oct 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $365 → $400 | $394.73 | +1.34% | 11 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 → $21 | $18.66 | +12.54% | 4 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $240 → $270 | $273.60 | -1.32% | 7 | Sep 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $430 | $455.98 | -5.70% | 6 | Sep 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $35 → $40 | $57.01 | -29.83% | 2 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Sell | $47 → $44 | $48.20 | -8.71% | 6 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $67.16 | +4.23% | 5 | Jul 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $9 → $13 | $15.88 | -18.14% | 4 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $68 | $81.83 | n/a | 6 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $182 | $71.01 | n/a | 12 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 → $160 | $121.93 | n/a | 15 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $15 | $6.80 | n/a | 11 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $4.42 | n/a | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $21.31 | n/a | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $260 | $325.22 | n/a | 12 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $11 | $10.90 | n/a | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $4 | $9.02 | n/a | 14 | Dec 3, 2024 |
Guardant Health
Oct 20, 2026
Reiterated: Buy
Price Target: $200
Current: $173.25
Upside: +15.44%
Agilent Technologies
Oct 13, 2026
Rated: Buy
Price Target: $175 → $190
Current: $175.96
Upside: +7.98%
Adaptive Biotechnologies
Oct 13, 2026
Reiterated: Hold
Price Target: $27
Current: $26.27
Upside: +2.78%
Avantor
Oct 13, 2026
Rated: Hold
Price Target: $14 → $15
Current: $17.29
Upside: -13.24%
Charles River Laboratories International
Oct 13, 2026
Rated: Buy
Price Target: $300 → $340
Current: $357.27
Upside: -4.83%
Danaher
Oct 13, 2026
Rated: Buy
Price Target: $220 → $240
Current: $232.97
Upside: +3.02%
GRAIL
Oct 13, 2026
Reiterated: Hold
Price Target: $120
Current: $139.91
Upside: -14.23%
Natera
Oct 13, 2026
Rated: Buy
Price Target: $355 → $435
Current: $404.90
Upside: +7.43%
Thermo Fisher Scientific
Oct 13, 2026
Rated: Buy
Price Target: $650 → $730
Current: $684.89
Upside: +6.59%
10x Genomics
Oct 13, 2026
Rated: Hold
Price Target: $40 → $70
Current: $72.96
Upside: -4.06%
Oct 9, 2026
Reiterated: Hold
Price Target: $5.5 → $5
Current: $5.89
Upside: -15.11%
Oct 9, 2026
Reiterated: Hold
Price Target: $1,450 → $1,575
Current: $1,669.62
Upside: -5.67%
Oct 5, 2026
Rated: Hold
Price Target: $20
Current: $19.88
Upside: +0.60%
Sep 22, 2026
Upgraded: Buy
Price Target: $365 → $400
Current: $394.73
Upside: +1.34%
Sep 18, 2026
Rated: Buy
Price Target: $19 → $21
Current: $18.66
Upside: +12.54%
Sep 17, 2026
Rated: Hold
Price Target: $240 → $270
Current: $273.60
Upside: -1.32%
Sep 14, 2026
Reiterated: Hold
Price Target: $430
Current: $455.98
Upside: -5.70%
Aug 17, 2026
Reiterated: Hold
Price Target: $35 → $40
Current: $57.01
Upside: -29.83%
Aug 4, 2026
Rated: Sell
Price Target: $47 → $44
Current: $48.20
Upside: -8.71%
Jul 10, 2026
Reiterated: Buy
Price Target: $70
Current: $67.16
Upside: +4.23%
Jul 9, 2026
Rated: Hold
Price Target: $9 → $13
Current: $15.88
Upside: -18.14%
Jul 15, 2025
Reiterated: Buy
Price Target: $100 → $68
Current: $81.83
Upside: n/a
Jul 15, 2025
Reiterated: Buy
Price Target: $200 → $182
Current: $71.01
Upside: n/a
Jun 11, 2025
Reiterated: Buy
Price Target: $130 → $160
Current: $121.93
Upside: n/a
May 20, 2025
Reiterated: Hold
Price Target: $20 → $15
Current: $6.80
Upside: n/a
May 9, 2025
Reiterated: Hold
Price Target: $10
Current: $4.42
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $19
Current: $21.31
Upside: n/a
Apr 24, 2025
Reiterated: Hold
Price Target: $260
Current: $325.22
Upside: n/a
Feb 27, 2025
Reiterated: Hold
Price Target: $10 → $11
Current: $10.90
Upside: n/a
Dec 3, 2024
Reiterated: Hold
Price Target: $5 → $4
Current: $9.02
Upside: n/a